Literature DB >> 25552734

Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios.

Giovanni Sotgiu1, Emanuele Pontali2, Giovanni Battista Migliori3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25552734     DOI： 10.1183/09031936.00145014

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  17 in total

1.  The multidrug-resistant tuberculosis threat: old problems and new solutions.

Authors:  Giovanni Sotgiu; Lia D'Ambrosio; Rosella Centis; Ida Mura; Paolo Castiglia; Antonio Spanevello; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

2.  Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives.

Authors:  Adrian Rendon; Simon Tiberi; Anna Scardigli; Lia D'Ambrosio; Rosella Centis; Jose A Caminero; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 3.  Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

Authors:  Lia D'Ambrosio; Rosella Centis; Simon Tiberi; Marina Tadolini; Margareth Dalcolmo; Adrian Rendon; Susanna Esposito; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

4.  Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress.

Authors:  Alberto L Garcia-Basteiro; Ernie Wong; Pouline M Van Oort; Catia Cilloniz; Giovanni Battista Migliori; Aran Singanayagam
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

5.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

6.  Linezolid induced retinopathy.

Authors:  Dae Hyun Park; Tae Kwann Park; Young-Hoon Ohn; Jong Sook Park; Jee Ho Chang
Journal:  Doc Ophthalmol       Date:  2015-11-03       Impact factor: 2.379

Review 7.  Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Authors:  Giovanni Sotgiu; Lia D'Ambrosio; Rosella Centis; Simon Tiberi; Susanna Esposito; Simone Dore; Antonio Spanevello; Giovanni Battista Migliori
Journal:  Int J Mol Sci       Date:  2016-03-12       Impact factor: 5.923

8.  Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Authors:  Soazic Grard; Gaud Catho; Florent Valour; Anissa Bouaziz; Thomas Perpoint; Evelyne Braun; François Biron; Patrick Miailhes; Tristan Ferry; Christian Chidiac; Pierre-Jean Souquet; Sébastien Couraud; Gérard Lina; Sylvain Goutelle; Nicolas Veziris; Oana Dumitrescu; Florence Ader
Journal:  Open Forum Infect Dis       Date:  2015-12-22       Impact factor: 3.835

Review 9.  New anti-tuberculosis drugs and regimens: 2015 update.

Authors:  Lia D'Ambrosio; Rosella Centis; Giovanni Sotgiu; Emanuele Pontali; Antonio Spanevello; Giovanni Battista Migliori
Journal:  ERJ Open Res       Date:  2015-05-06

Review 10.  Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.

Authors:  Akosua Adom Agyeman; Richard Ofori-Asenso
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-06-22       Impact factor: 3.944
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.